Eight stock picks in AI, obesity drugs, e-commerce and other growth areas beyond the S&P 500Market Watch • Thursday
Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.Market Watch • Tuesday
Novo Nordisk (NVO) Stock Falls Amid Market Uptick: What Investors Need to KnowZacks Investment Research • Tuesday
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated personsGlobeNewsWire • Monday
Novo Nordisk and Ginkgo Bioworks Are Teaming Up. Here's Why That's Bullish for Both Stocks.The Motley Fool • Monday
Novo Nordisk and Eli Lilly weight loss drugs may not be a silver bullet, but they have huge potential, says leading US bankProactive Investors • Monday
Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating - Novo Nordisk (NYSE:NVO)Benzinga • 04/12/24
EU probe of weight loss and diabetes drugs like Wegovy, Ozempic finds no link to suicidal thoughtsCNBC • 04/12/24
Obesity-drug power couple Novo Nordisk and Eli Lilly still have room to run, analysts sayMarket Watch • 04/12/24
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?Market Watch • 04/10/24
Novo Nordisk's Stock Could Get Another Boost, Thanks to This Huge DevelopmentThe Motley Fool • 04/10/24
Meet Europe's Mag 18. Novo Nordisk Stock, ASML, and Others Can Rival the Mag Seven.Barrons • 04/09/24